[go: up one dir, main page]

WO2023197005A3 - Small molecule inhibitors of enolase 1 and enolase 3 - Google Patents

Small molecule inhibitors of enolase 1 and enolase 3 Download PDF

Info

Publication number
WO2023197005A3
WO2023197005A3 PCT/US2023/065561 US2023065561W WO2023197005A3 WO 2023197005 A3 WO2023197005 A3 WO 2023197005A3 US 2023065561 W US2023065561 W US 2023065561W WO 2023197005 A3 WO2023197005 A3 WO 2023197005A3
Authority
WO
WIPO (PCT)
Prior art keywords
enolase
small molecule
molecule inhibitors
eno3
eno1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/065561
Other languages
French (fr)
Other versions
WO2023197005A2 (en
Inventor
Sanjay Malhotra
Dhanir TAILOR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of WO2023197005A2 publication Critical patent/WO2023197005A2/en
Publication of WO2023197005A3 publication Critical patent/WO2023197005A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns small molecule inhibitors or modulators of Enolase 1 (ENO1) and/or Enolase 3 (ENO3) that are useful in the treatment of cancers such as triple negative breast cancer, pancreatic cancer, and leukemias, including those in hyperglycemic and hyperinsulinemic subjects.
PCT/US2023/065561 2022-04-08 2023-04-07 Small molecule inhibitors of enolase 1 and enolase 3 Ceased WO2023197005A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263329366P 2022-04-08 2022-04-08
US63/329,366 2022-04-08

Publications (2)

Publication Number Publication Date
WO2023197005A2 WO2023197005A2 (en) 2023-10-12
WO2023197005A3 true WO2023197005A3 (en) 2023-11-30

Family

ID=88243859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/065561 Ceased WO2023197005A2 (en) 2022-04-08 2023-04-07 Small molecule inhibitors of enolase 1 and enolase 3

Country Status (1)

Country Link
WO (1) WO2023197005A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11987570B1 (en) * 2023-10-31 2024-05-21 King Faisal University 10-(2-hydroxyethyl)-9-(2-hydroxypyridin-3-yl)-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione as an antimicrobial compound
CN119405814A (en) * 2024-12-18 2025-02-11 青岛大学附属医院 Use of ENO1 as a target in the preparation of a pharmaceutical composition for the treatment of bladder cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103798A1 (en) * 2008-02-22 2009-08-27 Henkel Ag & Co. Kgaa 9-[4-(amino) phenyl] acridinium salts as cationic direct dyes for coloring keratinous fibers
US20170342086A1 (en) * 2015-02-26 2017-11-30 Ajay Kumar Compounds and methods for the treatment of drug resistance in cancer cells against paclitaxel
US20200375977A1 (en) * 2018-03-13 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Novel n-hydroxyethyl didehydroazapodophyllotoxins as gbp1 inhibitors and methods of overcoming treatment resistance in cancer
WO2021202886A1 (en) * 2020-04-02 2021-10-07 Board Of Regents, The University Of Texas System Methods for the mono-amidation of phosphates and phosphonates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103798A1 (en) * 2008-02-22 2009-08-27 Henkel Ag & Co. Kgaa 9-[4-(amino) phenyl] acridinium salts as cationic direct dyes for coloring keratinous fibers
US20170342086A1 (en) * 2015-02-26 2017-11-30 Ajay Kumar Compounds and methods for the treatment of drug resistance in cancer cells against paclitaxel
US20200375977A1 (en) * 2018-03-13 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Novel n-hydroxyethyl didehydroazapodophyllotoxins as gbp1 inhibitors and methods of overcoming treatment resistance in cancer
WO2021202886A1 (en) * 2020-04-02 2021-10-07 Board Of Regents, The University Of Texas System Methods for the mono-amidation of phosphates and phosphonates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREOLI ET AL.: "Identification of the First Inhibitor of the GBP1 :PIM1 Interaction. Implications for the Development of a New Class of Anticancer Agents against Paclitaxel Resistant Cancer Cells", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 19, 11 September 2014 (2014-09-11), pages 7916 - 7932, XP055636866, DOI: 10.1021/jm5009902 *
QIAO GAN, WU ANGUO, CHEN XIAOLIANG, TIAN YE, LIN XIUKUN: "Enolase 1, a Moonlighting Protein, as a Potential Target for Cancer Treatment", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 17, no. 14, 1 January 2021 (2021-01-01), pages 3981 - 3992, XP093115890, ISSN: 1449-2288, DOI: 10.7150/ijbs.63556 *

Also Published As

Publication number Publication date
WO2023197005A2 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
WO2023197005A3 (en) Small molecule inhibitors of enolase 1 and enolase 3
BR112023020773A2 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING CANCER, FOR REGULATING THE ACTIVITY OF A MUTANT PROTEIN, FOR INHIBITING THE PROLIFERATION OF A CELL POPULATION, FOR PREPARING A MUTANT PROTEIN AND FOR INHIBITING TUMOR METASTASIS, USE OF A COMPOUND AND PROCESS FOR SYNTHESISTING A COMPOUND
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
FR3107648B1 (en) anti-CD56 antibody-drug conjugates and their use in therapy
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
WO2023205702A3 (en) Modified exosomes and methods of use
MX2023013995A (en) Anthracycline antibody conjugates.
WO2021247794A3 (en) B7h3-targeting proteins and methods of use thereof
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
CA3246087A1 (en) Heterocyclic compounds as modulators of bcl6 as ligand directed degraders
MX2021011524A (en) Prmt5 inhibitors and uses thereof.
WO2022214869A3 (en) 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
MX2023006087A (en) Lyophilized formulations of tegavivint.
WO2005019269A3 (en) Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2022119830A8 (en) Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
WO2024137545A9 (en) Arnatar compounds and methods for enhanced cellular uptake
MX2024005589A (en) Lurbinectedin and atezolizumab combinations.
NO20016391D0 (en) Process for the preparation of polycation-based bioconjugates suitable for the transport of various types of active substances in the body
WO2023019186A3 (en) Compositions and methods for treatment of cancer
WO2022081738A3 (en) Polymer-conjugated microbubbles for high drug/gene loading
WO2021178960A3 (en) Compositions and methods for treatment of cancer
WO2024077118A3 (en) Multispecific proteins and related methods
WO2025022285A3 (en) Psma-targeting radioligand treatment regimen
EP4603145A3 (en) Treating pain associated with central sensitization

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23785695

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23785695

Country of ref document: EP

Kind code of ref document: A2